2020
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.Peer-Reviewed Original ResearchInsulin-naïve patientsInsulin useBackground glucose-lowering therapyEMPA-REG OUTCOMEInsulin dose increasesInsulin-treated patientsGlucose-lowering therapyEmpagliflozin 10T2D durationInsulin doseT2D diagnosisInsulin needsPlaceboPatientsWeight gainKey covariatesDose increaseInsulinTreatment effectsNew initiationHypoglycemiaT2DTherapyYrDiagnosisCONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL
Docherty K, Jackson A, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, Desai A, Diez M, Howlett J, Ljungman C, O'Meara E, Petrie M, Schou M, Pham V, McMurray J. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 656. DOI: 10.1016/s0735-1097(20)31283-3.Peer-Reviewed Original Research
2016
How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies
Inzucchi S, Matthews D. How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016, 471-492. DOI: 10.1002/9781118924853.ch33.Peer-Reviewed Original ResearchType 2 diabetesMultiple pathophysiological defectsGlucose-lowering agentsSide effect profileAmerican Diabetes AssociationRecent position statementStudy of DiabetesMechanism of actionComplementary regimensManagement of peopleDiabetes AssociationCombination therapyPathophysiological defectsAntihyperglycemic agentsDrug therapyClinical practiceType 2Clinical useEuropean AssociationDiabetesIndividual riskPosition statementTherapyAssociationRegimens
2005
Oral Agents for Type 2 Diabetes: An Update
Kimmel B, Inzucchi S. Oral Agents for Type 2 Diabetes: An Update. Clinical Diabetes 2005, 23: 64-76. DOI: 10.2337/diaclin.23.2.64.Peer-Reviewed Original ResearchOral pharmacological therapyType 2 diabetesOptimal metabolic controlClinical trial dataRational therapeutic strategiesMechanism of actionOral agentsPharmacological therapyNonglycemic effectsCommon conditionTherapeutic strategiesDrug categoriesMetabolic controlType 2Trial dataDiabetesPatientsTherapyProper use